NCT07364422 2026-01-23To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric CancerOnconic Therapeutics Inc.Phase 1/2 Not yet recruiting49 enrolled